Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis

Cancer Treatment Reviews

Volumn 36, Issue 1, 2010, Pages 69-74

  Mauri, Davide ^a,b   Kamposioras, Konstantinos ^b   Tsali, Lamprini ^a,b   Bristianou, Magdalini ^a,b   Valachis, Antonis ^a,b   Karathanasi, Ioanna ^b   Georgiou, Christos ^a   Polyzos, Nikolaos P ^b,c  

^a General Hospital of Lamia   (Greece)

^b Panhellenic Association for Continual Medical Research (PACMeR)   (Greece)

^c UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Advanced; Breast cancer; Docetaxel; Every three weeks; Metastatic; Paclitaxel; Taxanes; Weekly

Indexed keywords

DOCETAXEL; PACLITAXEL; TAXANE DERIVATIVE;

ADVANCED CANCER; ANEMIA; BREAST CANCER; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIPHORA; FATIGUE; FEBRILE NEUTROPENIA; GENETIC HETEROGENEITY; HUMAN; META ANALYSIS; NAIL DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TAXOIDS;

EID: 74749083311     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.10.006     Document Type: Review

References (26)

1. Mauri D., Polyzos N.P., Salanti G., Pavlidis N., and Ioannidis J.P. Multiple treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 100 24 (2008) 1780-1791
2. Esteva F.J., Valero V., Booser D., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 1800-1808
3. Hainsworth J.D., Burris H.A., Erland J.B., et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16 (1998) 2164-2168
4. Tomiak E., Piccart M.J., Kerger J., et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12 (1994) 1458-1467
5. Burstein H.J., Manola J., Younger J., et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18 (2000) 1212-1219
6. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., and Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8 (2007) 16
7. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 3 (1986) 177-188 Sep
8. Cochran W. The combination of estimates from different experiments. Biometrics 10 (1954) 101-129
9. Higgins J.P.T., and Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002) 1539-1558
10. Higgins J.P.T., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
11. Rivera E., Mejia J.A., Arun B.K., Adinin R.B., et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112 7 (2008) 1455-1461
12. Tabernero J., Climent M.A., Lluch A., et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15 9 (2004) 1358-1365
13. Seidman A.D., Berry D., Cirrincione C., et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26 10 (2008) 1642-1649
14. Fountzilas G., Dafni U., Dimopoulos M.A., et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 115 1 (2009) 87-99
15. Frasci G., D'Aiuto G., Comella P., et al. Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study. Br J Cancer 95 8 (2006) 1005-1012
16. Khoo K.S., Manzoor Zaidi S.H., Srimuninnimit V., et al. Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study. Eur J Cancer 42 12 (2006) 1797-1806
17. Sedky L., El-Dine I.S., Hazme B., Samir Motawe S., and Fahmi R. Weekly docetaxel vs every 3-week in advanced breast cancer: results of a pilot comparative study. Proc Am Soc Clin Oncol 21 (2002) [abstr 2013]
18. Gradishar W.J., Krasnojon D., Cheporov S., et al. Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer. Eur J Cancer 5 Suppl. 4 (2007) 215 abstr P#2106
19. Frasci G., D'Aiuto G., Comella P., et al. Weekly cisplatin-epirubicin-paclitaxel with G-CSF support (PET) vs. triweekly epirubicin-paclitaxel (ET) in metastatic breast cancer (MBC). J Clin Oncol 23 16S, June 1 Suppl. (2005) 580
20. Sikov W.M., Akerley W., Kahanic S., et al. Multicenter, 3-arm randomized study of high-dose weekly paclitaxel (HDWP) versus standard-dose weekly paclitaxel (SDWP) for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21 (2002) [abstr 134]
21. Willemse P., Munck L., Creemers G.J., et al. A phase III study on the efficacy and safety of docetaxel, every three weeks or as a weekly regimen in patients with metastatic breast cancer. Breast Cancer Res Treat 106 Suppl. 1 (2007) S70 [abstract 1083]
22. Gradishar W.J., Krasnojon D., Cheporov S., et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27 22 (2009) 3611-3619
23. Saad E.D., and Katz A. Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. Ann Oncol 20 3 (2009) 460-464
24. Stewart L.A., and Tierney J.F. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 25 (2002) 76-97
25. Clarke M., Stewart L., Pignon J.P., and Bijnens L. Individual patient data metanalysis in cancer. Br J Cancer 77 (1998) 2036-2044
26. Lau J., Ioannidis J.P., and Schmid C.H. Summing up evidence: one answer is not always enough. Lancet 351 (1998) 123-127